Aller directement au menu principal Aller directement au contenu principal Aller au pied de page
Cortica

Perspective

Vol. 3 No. 2 (2024): La multidisciplinarité de la psychologie de la santé & des neurosciences

Quel est l'impact potentiel du traitement du trouble lié à l’usage de l’alcool par le LSD : Une revue systématique d’essaies contrôlés randomisés, méthodes PRISMA

  • Maya Oberson
DOI
https://doi.org/10.26034/cortica.2024.6099
Soumise
September 20, 2024
Publié-e
2024-09-21

Résumé

Dans ce travail, l’objectif principal est d’explorer les effets et l’efficacité du diéthylamide de l'acide lysergique, plus communément connu sous le nom de LSD, dans le traitement du trouble lié à l’usage de l’alcool. Une recherche systématique, s’appuyant sur différentes bases de données, a été menée dans le but de sélectionner des articles traitant de la problématique en question. À la suite de cette sélection d’études, sept d’entre elles ont été retenues. Les résultats de cette revue systématique, qui s'appuie sur la méthode « Preferred Reporting Items for Systematic reviews and Meta-Analyses » [PRISMA] (Moher et al., 2009), laissent penser que le LSD ne démontre pas une efficacité significative en comparaison avec d’autres traitements sur la réduction de la consommation d’alcool chez les individus traités. De plus, les quelques effets bénéfiques obtenus lors des différentes expériences ne semblent pas perdurer à long terme, ce qui ne suggère pas que le LSD puisse être un traitement durable susceptible d’amener à une réduction continue de la dépendance à l’alcool. Les résultats présentés dans cette revue systématique ne peuvent pas être généralisés et doivent être abordés avec une certaine réserve, car les études sélectionnées présentent des hétérogénéités. Néanmoins, ce travail souligne l'importance de poursuivre les investigations dans ce domaine. De futures études menées de manière contrôlée et éthique sont nécessaires pour obtenir des résultats fiables et utiles pour le futur, tant pour la compréhension des mécanismes sous-jacents que pour le développement de nouvelles approches thérapeutiques dans le traitement des troubles liés à l'usage de l'alcool. Ces résultats mettent en lumière les défis persistants dans la recherche de traitements efficaces pour le trouble lié à l'usage de l’alcool et soulignent l'importance de diversifier les approches thérapeutiques pour mieux répondre aux besoins des patient-e-s.

Références

  1. Abramson—1966—LSD in Psychotherapy and Alcoholism.pdf. (n.d.). Retrieved January 29, 2024, from https://www.samorini.it/doc1/alt_aut/ad/abramson-the- use-of-lsd-in-psychotherapy-and-alcoholism.pdf
  2. Ammons, R. B., & Ammons, C. H. (1962). The Quick Test (QT): Provisional Manual,. Psychological Reports, 11(1), 111–161. https://doi.org/10.1177/003329416201100106
  3. Archibald, L., Brunette, M. F., Wallin, D. J., & Green, A. I. (2019). Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder. Alcohol Research: Current Reviews, 40(1), arcr.v40.1.06. https://doi.org/10.35946/arcr.v40.1.06
  4. Bowen, W. T., Soskin, R. A., & Chotlos, J. W. (1970). LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY. The Journal of Nervous and Mental Disease, 150(2), 111.
  5. Breslow, R. E., Klinger, B. I., & Erickson, B. J. (1996). Acute intoxication and substance abuse among patients presenting to a psychiatric emergency service. General Hospital Psychiatry, 18(3), 183–191. https://doi.org/10.1016/0163-8343(96)00019-9
  6. Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V., Bühler, K. M., Giné, E., & López-Moreno, J. A. (2022). Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. Addiction Biology, 27(6), 1–13. https://doi.org/10.1111/adb.13229
  7. Castrén, E. (2014). Neurotrophins and psychiatric disorders. Handbook of Experimental Pharmacology, 220, 461–479. https://doi.org/10.1007/978-3- 642-45106-5_17
  8. Chwelos, N., Blewett, D. B., Smith, C. M., & Hoffer, A. (1959). Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly Journal of Studies on Alcohol, 20, 577–590.
  9. Compton, W. M., Thomas, Y. F., Stinson, F. S., & Grant, B. F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 64(5), 566–576. https://doi.org/10.1001/archpsyc.64.5.566
  10. Cook, T. A. R., Luczak, S. E., Shea, S. H., Ehlers, C. L., Carr, L. G., & Wall, T. L.
  11. (2005). Associations of ALDH2 and ADH1B genotypes with response to alcohol in Asian Americans. Journal of Studies on Alcohol, 66(2), 196–204. https://doi.org/10.15288/jsa.2005.66.196
  12. Cranford, J. A., Nolen-Hoeksema, S., & Zucker, R. A. (2011). Alcohol involvement as a function of co-occurring alcohol use disorders and major depressive episode: Evidence from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence, 117(2–3), 145–151. https://doi.org/10.1016/j.drugalcdep.2011.01.011
  13. Crocq, M.-A., & Guelfi, J.-D. (2015a). DSM-5: Manuel diagnostique et statistique des troubles mentaux (5e éd). Elsevier Masson.
  14. De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. (2016). d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. International Journal of Molecular Sciences, 17(11), Article 11. https://doi.org/10.3390/ijms17111953
  15. Dick, D. M., Bierut, L., Hinrichs, A., Fox, L., Bucholz, K. K., Kramer, J., Kuperman, S., Hesselbrock, V., Schuckit, M., Almasy, L., Tischfield, J., Porjesz, B., Begleiter, H., Nurnberger, J., Xuei, X., Edenberg, H. J., & Foroud, T. (2006). The role of GABRA2 in risk for conduct disorder and alcohol and drug dependence across developmental stages. Behavior Genetics, 36(4), 577– 590. https://doi.org/10.1007/s10519-005-9041-8
  16. Egervari, G., Siciliano, C. A., Whiteley, E. L., & Ron, D. (2021). Alcohol and the brain: From genes to circuits. Trends in Neurosciences, 44(12), 1004–1015. https://doi.org/10.1016/j.tins.2021.09.006
  17. Ekstrom, R.B, J.W, Harman, & H.H. (1976). Manual for kit of factor-referenced cognitive tests.
  18. Elvig, S. K., McGinn, M. A., Smith, C., Arends, M. A., Koob, G. F., & Vendruscolo, L. F. (2021). Tolerance to alcohol: A critical yet understudied factor in alcohol addiction. Pharmacology Biochemistry and Behavior, 204, 173155. https://doi.org/10.1016/j.pbb.2021.173155
  19. Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology (Oxford, England), 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793
  20. Gicquel, T., Lepage, S., & Morel, I. (2015a). Histoire du LSD. De l’ergot de seigle à
  21. l’utilisation thérapeutique. La Presse Médicale, 44(7–8), 832.
  22. https://doi.org/10.1016/j.lpm.2015.04.033
  23. Gordon, T. (2006). Les armes secrètes de la C.I.A : Tortures, manipulations et armes
  24. chimiques. Editions du Septentrion.
  25. Gough, H. G. (1990). The California Psychological Inventory. In Testing in counseling
  26. practice (pp. 37–62). Lawrence Erlbaum Associates, Inc.
  27. Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Pickering, R.
  28. P. (2004a). Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61(4), 361–368. https://doi.org/10.1001/archpsyc.61.4.361
  29. Green, A. I. (2006). Treatment of schizophrenia and comorbid substance abuse: Pharmacologic approaches. The Journal of Clinical Psychiatry, 67 Suppl 7, 31–35; quiz 36–37.
  30. Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99–120. https://doi.org/10.1016/j.bbr.2014.07.016
  31. Hartigan, F. (2001). Bill W.: A Biography of Alcoholics Anonymous Cofounder Bill Wilson biography of alcoholics anonymous cofounder Bill Wilson. St. Martins Press.
  32. Hayes, A., Herlinger, K., Paterson, L., & Lingford-Hughes, A. (2020). The neurobiology of substance use and addiction: Evidence from neuroimaging and relevance to treatment. BJPsych Advances, 26(6), 367–378. https://doi.org/10.1192/bja.2020.68
  33. Hofmann, A. (1980). LSD, my problem child. McGraw-Hill.
  34. Hollister, L. E., Shelton, J., & Krieger, G. (1969). A Controlled Comparison of
  35. Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics. American Journal of Psychiatry, 125(10), 1352–1357. https://doi.org/10.1176/ajp.125.10.1352
  36. Institut national de la santé et de la recherche médicale [INSERM]. (2021). Inserm. https://www.inserm.fr/
  37. Jackson, D. N., & Messick, S. (1964). The Differential Personality Inventory. James SL, Abate D, Abate KH, Abay SM, Abbafati C, & Abbasi N. (2018). Global,
  38. regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392(10159), 1789–1858. https://doi.org/10.1016/S0140- 6736(18)32279-7
  39. Johnson. (1969). LSD in the Treatment of Alcoholism. American Journal of Psychiatry, 126(4), 481–487. https://doi.org/10.1176/ajp.126.4.481
  40. Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010
  41. Kervadec, E., Benyamina, A., & Roméo, B. (2023). Psychédéliques et addictions: Réémergence d’une modalité thérapeutique pour le traitement des troubles liés à l’usage de substances. L’information psychiatrique, 99(10), 693–702. https://doi.org/10.1684/ipe.2023.2656
  42. Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017). Psychedelic Drugs in Biomedicine. Trends in Pharmacological Sciences, 38(11), 992–1005. https://doi.org/10.1016/j.tips.2017.08.003
  43. Laucht, M., Becker, K., Blomeyer, D., & Schmidt, M. H. (2007). Novelty seeking involved in mediating the association between the dopamine D4 receptor gene exon III polymorphism and heavy drinking in male adolescents: Results from a high-risk community sample. Biological Psychiatry, 61(1), 87–92. https://doi.org/10.1016/j.biopsych.2006.05.025
  44. Le Daré, B., Lagente, V., & Gicquel, T. (2019). Ethanol and its metabolites: Update on toxicity, benefits, and focus on immunomodulatory effects. Drug Metabolism Reviews, 51(4), 545–561. https://doi.org/10.1080/03602532.2019.1679169
  45. Lea, T., Amada, N., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020). Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology, 237(5), 1521–1532. https://doi.org/10.1007/s00213-020-05477-0
  46. Lee, M. A., & Shlain, B. (1992). Acid Dreams: The Complete Social History of LSD : the CIA, the Sixties, and Beyond. Grove Press.
  47. Levine, J., & Ludwig, A. M. (1967, March). The Psychiatric Evaluation Profile (PEP):
  48. A new self-report inventory. The Psychiatric Evaluation Profile (PEP): A new self-report inventory, the Twelfth Annual Conference of the VA Cooperative Studies in Psychiatry, Denver, Colorado.
  49. Liechti, M. E. (2017a). Modern Clinical Research on LSD. Neuropsychopharmacology, 42(11), Article 11. https://doi.org/10.1038/npp.2017.86
  50. Longo, Dan L, Harrison, & Tinsley Randolph. (2012). Harrison’s principles of internal medicine. (18th ed.). New York : McGraw-Hill.
  51. Lovinger, D. M. (1997). Serotonin’s Role in Alcohol’s Effects on the Brain. Alcohol Health and Research World, 21(2), 114–120.
  52. Ludwig, A., Levine, J., Stark, L., & Lazar, R. (1969). A Clinical Study of LSD Treatment in Alcoholism. American Journal of Psychiatry, 126(1), 59–69. https://doi.org/10.1176/ajp.126.1.59
  53. Ludwig, A. M. (1968). Relationship of attitude to behavior: Preliminary results and implications for treatment evaluation studies. In Research in psychotherapy (pp. 471–487). American Psychological Association. https://doi.org/10.1037/10546-023
  54. Mateo, S. (2020). Procédure pour conduire avec succès une revue de littérature selon la méthode PRISMA. Kinésithérapie, La Revue, 20(226), 29–37. https://doi.org/10.1016/j.kine.2020.05.019
  55. McGlothlin, W., Cohen, S., & McGlothlin, M. S. (1967). Long lasting effects of LSD on normals. Archives of General Psychiatry, 17(5), 521–532. https://doi.org/10.1001/archpsyc.1967.01730290009002
  56. McGovern, P. E., Zhang, J., Tang, J., Zhang, Z., Hall, G. R., Moreau, R. A., Nuñez, A., Butrym, E. D., Richards, M. P., Wang, C.-S., Cheng, G., Zhao, Z., & Wang, C. (2004). Fermented beverages of pre- and proto-historic China. Proceedings of the National Academy of Sciences of the United States of America, 101(51), 17593–17598. https://doi.org/10.1073/pnas.0407921102
  57. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, T. P. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
  58. Muttoni, S., Ardissino, M., & John, C. (2019). Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders, 258, 11–24. https://doi.org/10.1016/j.jad.2019.07.076
  59. Nichols, D. E. (2001). LSD and Its Lysergamide Cousins. 2.
  60. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355.
  61. https://doi.org/10.1124/pr.115.011478
  62. Nichols, D. E., & Nichols, C. D. (2008). Serotonin Receptors. Chemical Reviews,
  63. (5), 1614–1641. https://doi.org/10.1021/cr078224o
  64. Nurnberger, J. I., & Bierut, L. J. (2007). Seeking the connections: Alcoholism and our
  65. genes. Scientific American, 296(4), 46–53.
  66. https://doi.org/10.1038/scientificamerican0407-46
  67. Office fédéral de la santé publique [OFSP], O. fédéral de la santé publique. (1947).
  68. Office fédéral de la santé publique [OFSP].
  69. https://www.bag.admin.ch/bag/fr/home.html
  70. Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C., & Grof, S. (1970). The
  71. Experimental Use of Psychedelic (LSD) Psychotherapy. JAMA, 212(11),
  72. –1863. https://doi.org/10.1001/jama.1970.03170240060010 Passie, T. (1997). Psycholytic and psychedelic therapy research 1931 - 1995: A
  73. complete international bibliography. Laurentius Publ.
  74. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008).
  75. The Pharmacology of Lysergic Acid Diethylamide: A Review. CNS Neuroscience & Therapeutics, 14(4), 295–314. https://doi.org/10.1111/j.1755- 5949.2008.00059.x
  76. Pervin, Z., & Stephen, J. M. (2021). Effect of alcohol on the central nervous system to develop neurological disorder: Pathophysiological and lifestyle modulation can be potential therapeutic options for alcohol-induced neurotoxication. AIMS Neuroscience, 8(3), 390–413. https://doi.org/10.3934/Neuroscience.2021021
  77. Petrakis, I. L., Gonzalez, G., Rosenheck, R., & Krystal, J. H. (2002). Comorbidity of Alcoholism and Psychiatric Disorders. Alcohol Research & Health, 26(2), 81– 89.
  78. Porter, R. (1987). Jean-Charles Sournia, Histoire de l’alcoolisme, Paris, Flammarion, 1986, 8vo, pp. 323, Fr. 125.00 (paperback). Medical History, 31(3), 372–373. https://doi.org/10.1017/S0025727300047050
  79. Ross, C. A. (2017). LSD experiments by the United States Army. History of Psychiatry, 28(4), 427–442. https://doi.org/10.1177/0957154X17717678 Savage, C. (1952). Lysergic acid diethylamide; a clinical-psychological study. The
  80. American Journal of Psychiatry, 108(12), 896–900.
  81. https://doi.org/10.1176/ajp.108.12.896
  82. Scarpellini G. (2020). IDostatistics. https://idostatistics.com/cohen-kappa-free-
  83. calculator/
  84. Schiff, P. L. (2006). Ergot and its alkaloids. American Journal of Pharmaceutical
  85. Education, 70(5), 98. https://doi.org/10.5688/aj700598
  86. Schuckit, M. A. (1994). Low level of response to alcohol as a predictor of future
  87. alcoholism. The American Journal of Psychiatry, 151(2), 184–189.
  88. https://doi.org/10.1176/ajp.151.2.184
  89. Schuckit, M. A. (2009). Alcohol-use disorders. The Lancet, 373(9662), 492–501.
  90. https://doi.org/10.1016/S0140-6736(09)60009-X
  91. Shelton, J., Hollister, L. E., & Gocka, E. F. (1969). The drinking behavior interview.
  92. (An attempt to quantify alcoholic impairment). Diseases of the Nervous
  93. System, 30(7), 464–467.
  94. Smart, R. G., Storm, T., Baker, E. F., & Solursh, L. (1966). A controlled study of
  95. lysergide in the treatment of alcoholism. 1. The effects on drinking behavior.
  96. Quarterly Journal of Studies on Alcohol, 27(3), 469–482.
  97. Stephen Rich, J., & Martin, P. R. (2014). Co-occurring psychiatric disorders and
  98. alcoholism. Handbook of Clinical Neurology, 125, 573–588.
  99. https://doi.org/10.1016/B978-0-444-62619-6.00033-1
  100. Stoll, A. (1945). Les alcaloïdes de l’ergot. Experientia, 1(8), 250–262.
  101. https://doi.org/10.1007/BF02151732
  102. Swift, R. M., & Aston, E. R. (2015). Pharmacotherapy for Alcohol Use Disorder:
  103. Current and Emerging Therapies. Harvard Review of Psychiatry, 23(2), 122.
  104. https://doi.org/10.1097/HRP.0000000000000079
  105. Timberlake, D. S., Hopfer, C. J., Rhee, S. H., Friedman, N. P., Haberstick, B. C.,
  106. Lessem, J. M., & Hewitt, J. K. (2007). College attendance and its effect on drinking behaviors in a longitudinal study of adolescents. Alcoholism, Clinical and Experimental Research, 31(6), 1020–1030. https://doi.org/10.1111/j.1530- 0277.2007.00383.x
  107. Tomsovic, M., & Edwards, R. V. (1970). Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: A controlled evaluation. Quarterly Journal of Studies on Alcohol, 31(4), 932–949.
  108. Tucker, G. J., Quinlan, D., & Harrow, M. (1972). Chronic hallucinogenic drug use and
  109. thought disturbance. Archives of General Psychiatry, 27(4), 443–447.
  110. https://doi.org/10.1001/archpsyc.1972.01750280013003
  111. Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic
  112. medicine: A re-emerging therapeutic paradigm. CMAJ : Canadian Medical
  113. Association Journal, 187(14), 1054–1059. https://doi.org/10.1503/cmaj.141124 Vardy, M. M., & Kay, S. R. (1983). LSD psychosis or LSD-induced schizophrenia? A
  114. multimethod inquiry. Archives of General Psychiatry, 40(8), 877–883.
  115. https://doi.org/10.1001/archpsyc.1983.01790070067008
  116. Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman,
  117. L., Wall, M., Nutt, D. J., & Erritzoe, D. (2023). Psychedelic therapy in the treatment of addiction: The past, present and future. Frontiers in Psychiatry, 14. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.118 3740